Shire says Treasury rules won't nix deal for US-based Baxalta

federal building exterior

The pharma world may be abuzz with news of Pfizer's ($PFE) cancelled merger with Allergan ($AGN) in the wake of a tax crackdown. But make no mistake--Shire's merger with Baxalta is still on.

Shire CEO Flemming Ornskov

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

The transaction between the two, agreed upon in January, will proceed as planned, Ireland-based Shire ($SHPG) said Wednesday, and it expects to seal the deal by the middle of this year.

The tie-up "is based on a strong strategic rationale to create the leading global biotechnology company focused on rare diseases," Shire said--rather than on tax savings that could be curtailed by a new slate of rules the U.S. Treasury Department rolled out Monday.

That's not to say tax savings didn't figure into Shire's pursuit of the U.S.-based Baxalta ($BXLT). When it made its first bid for the Illinois pharma, it cited "benefits from our tax structure"--which it gained with a 2008 move to Ireland--among reasons Baxalta should want to join forces.

But Shire knew better than to structure a deal on tax benefits alone. After all, the company itself was the victim of new Treasury tax rules back in 2014, when buyer AbbVie ($ABBV) pulled the plug on its $55 billion Shire acquisition.

Instead, Shire sees Baxalta helping it build a global rare-disease leader, even if analysts--and at one time, Baxalta itself--have harbored their fair share of doubts. Baxalta specializes in hemophilia, a competitive market where new drugs could decimate its business going forward, Bernstein analyst Ronny Gal wrote late last year. Even if they don't, that hemophilia focus may not translate into easy savings when combined with the rest of Shire's rare-disease portfolio.

"An acquirer like Shire isn't just going to find easy savings from a combination with dissimilar assets," Baxalta CEO Ludwig Hantson told investors last August.

- read Shire's release 

Special Report: The 25 most influential people in biopharma in 2015 - Flemming Ornskov - Shire | Pharma's top 10 M&A deals of 2014


Suggested Articles

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.